Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Helmut Frieß

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5109847207. Sources: OpenAlex.

Their work

Papers
57 (first author 5, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
218
Papers, trials and grants by year

2011: 3 papers · 2012: 6 papers · 2013: 3 papers · 2014: 4 papers · 2015: 7 papers · 2016: none · 2017: 2 papers · 2018: 8 papers · 2019: 4 papers · 2020: 8 papers · 2021: 4 papers · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: 4 papers

Papers 50 of 57

  1. ARP2/3 complex affects myofibroblast differentiation and migration in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.35246↗
  2. Sensory neurons drive pancreatic cancer progression through glutamatergic neuron-cancer pseudo-synapses. Co-author DOI 10.1016/j.ccell.2025.09.003↗
  3. Extent of N-glycosylation of the metalloproteinase inhibitor and cytokine TIMP-1 determines pancreatic cancer cell proliferation and survival via CD63. Co-author DOI 10.1016/j.jbc.2025.110211↗
  4. Disrupting AGR2/IGF1 paracrine and reciprocal signaling for pancreatic cancer therapy. Co-author DOI 10.1016/j.xcrm.2024.101927↗
  5. Dynamics and cytokinic regulation of immune cell infiltration in genetically engineered mouse models of pancreatic cancer dictate the sensitivity to immunother… Co-author DOI 10.1002/cac2.12496↗
  6. Neoadjuvant chemotherapy is associated with suppression of the B cell-centered immune landscape in pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fimmu.2024.1378190↗
  7. Phenotype screens of murine pancreatic cancer identify a Tgf-α-Ccl2-paxillin axis driving human-like neural invasion. Co-author DOI 10.1172/jci166333↗
  8. Molecular Profiling in Pancreatic Cancer: Current Role and Its Impact on Primary Surgery. Co-author DOI 10.1159/000519755↗
  9. Targeting Aggressive Fibroblasts to Enhance the Treatment of Pancreatic Cancer. Co-author DOI 10.1080/14728222.2021.1857727↗
  10. Effects of COVID-19 Pandemic on the Treatment of Pancreatic Cancer: A Perspective from Central Europe. Co-author DOI 10.1159/000513157↗
  11. [18F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13550-021-00808-4↗
  12. Patterns and Relevance of Langerhans Islet Invasion in Pancreatic Cancer. Co-author DOI 10.3390/cancers13020249↗
  13. [Neoadjuvant treatment of primarily resectable and borderline resectable pancreatic cancer]. First author DOI 10.1007/s00104-019-01093-7↗
  14. Neoadjuvant therapy in pancreatic cancer: what is the true oncological benefit? Co-author DOI 10.1007/s00423-020-01946-4↗
  15. Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer. Co-author DOI 10.1016/j.pan.2020.06.012↗
  16. Neoadjuvant Therapy Remodels the Pancreatic Cancer Microenvironment via Depletion of Protumorigenic Immune Cells. Co-author DOI 10.1158/1078-0432.ccr-19-1864↗
  17. Implementing cell-free DNA of pancreatic cancer patient-derived organoids for personalized oncology. Co-author DOI 10.1172/jci.insight.137809↗
  18. Indirect cholinergic activation slows down pancreatic cancer growth and tumor-associated inflammation. Co-author DOI 10.1186/s13046-020-01796-4↗
  19. ALDH1A3 Accelerates Pancreatic Cancer Metastasis by Promoting Glucose Metabolism. Co-author DOI 10.3389/fonc.2020.00915↗
  20. Multiparametric Modelling of Survival in Pancreatic Ductal Adenocarcinoma Using Clinical, Histomorphological, Genetic and Image-Derived Parameters. Co-author DOI 10.3390/jcm9051250↗
  21. Oligometastatic pulmonary metastasis in pancreatic cancer patients: Safety and outcome of resection. Co-author DOI 10.1016/j.suronc.2019.08.010↗
  22. Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1159/000493466↗
  23. A machine learning algorithm predicts molecular subtypes in pancreatic ductal adenocarcinoma with differential response to gemcitabine-based versus FOLFIRINOX … Co-author DOI 10.1371/journal.pone.0218642↗
  24. Venous resection during pancreatectomy for pancreatic cancer: a systematic review. Co-author DOI 10.21037/tgh.2019.06.01↗
  25. Meta-analysis of the impact of neoadjuvant therapy on patterns of recurrence in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/bjs5.46↗
  26. Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. Co-author DOI 10.1016/s1470-2045(18)30098-6↗
  27. A look at the progress of treating pancreatic cancer over the past 20 years. First author DOI 10.1080/14737140.2018.1428093↗
  28. R0 Versus R1 Resection Matters after Pancreaticoduodenectomy, and Less after Distal or Total Pancreatectomy for Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000002345↗
  29. Insulin/IGF-driven cancer cell-stroma crosstalk as a novel therapeutic target in pancreatic cancer. Co-author DOI 10.1186/s12943-018-0806-0↗
  30. Outcomes After Distal Pancreatectomy with Celiac Axis Resection for Pancreatic Cancer: A Pan-European Retrospective Cohort Study. Co-author DOI 10.1245/s10434-018-6391-z↗
  31. Correction to: Outcomes After Distal Pancreatectomy with Celiac Axis Resection for Pancreatic Cancer: A Pan-European Retrospective Cohort Study. Co-author DOI 10.1245/s10434-018-6442-5↗
  32. Pancreatic cancer: disease dynamics, tumor biology and the role of the microenvironment. First author DOI 10.18632/oncotarget.24019↗
  33. The impact of neoadjuvant therapy on the histopathological features of pancreatic ductal adenocarcinoma - A systematic review and meta-analysis. Co-author DOI 10.1016/j.ctrv.2017.03.003↗
  34. IL-4 mRNA Is Downregulated in the Liver of Pancreatic Cancer Patients Suffering from Cachexia. Co-author DOI 10.1080/01635581.2017.1247885↗
  35. Kif20a inhibition reduces migration and invasion of pancreatic cancer cells. Co-author DOI 10.1016/j.jss.2015.03.070↗
  36. Neural plasticity in pancreatitis and pancreatic cancer. First author DOI 10.1038/nrgastro.2015.166↗
  37. Back pain as a potential indicator of local recurrence in pancreatic cancer. Co-author DOI 10.1093/jscr/rjv127↗
  38. Outcomes of resections for pancreatic adenocarcinoma with suspected venous involvement: a single center experience. Co-author DOI 10.1186/s12893-015-0086-1↗
  39. Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience. Co-author DOI 10.1245/s10434-015-4851-2↗
  40. Hypoxia-induced endoplasmic reticulum stress characterizes a necrotic phenotype of pancreatic cancer. Co-author DOI 10.18632/oncotarget.5168↗
  41. Pancreatic cancer - lessons from the past decade. First author DOI 10.4103/0971-5851.158821↗
  42. The role of inflammation in pancreatic cancer. Last author DOI 10.1007/978-3-0348-0837-8_6↗
  43. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Co-author DOI 10.1016/j.surg.2014.02.001↗
  44. Extended pancreatectomy in pancreatic ductal adenocarcinoma: definition and consensus of the International Study Group for Pancreatic Surgery (ISGPS). Co-author DOI 10.1016/j.surg.2014.02.009↗
  45. The neurotrophic factor neurturin contributes toward an aggressive cancer cell phenotype, neuropathic pain and neuronal plasticity in pancreatic cancer. Co-author DOI 10.1093/carcin/bgt312↗
  46. [S3-guideline exocrine pancreatic cancer]. Co-author DOI 10.1055/s-0033-1356220↗
  47. Cachexia in patients with chronic pancreatitis and pancreatic cancer: impact on survival and outcome. Co-author DOI 10.1080/01635581.2013.804580↗
  48. Perineural mast cells are specifically enriched in pancreatic neuritis and neuropathic pain in pancreatic cancer and chronic pancreatitis. Co-author DOI 10.1371/journal.pone.0060529↗
  49. Prolyl hydroxylase-2 (PHD2) exerts tumor-suppressive activity in pancreatic cancer. Co-author DOI 10.1002/cncr.26344↗
  50. Palliative resections versus palliative bypass procedures in pancreatic cancer--a systematic review. Co-author DOI 10.1016/j.amjsurg.2011.05.004↗

Closest collaborators

The 25 strongest of 218 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. İhsan Ekin Demir · 21 shared papers, 2013–2025 · strength 2.31
  2. Guralp Onur Ceyhan · 19 shared papers, 2013–2025 · strength 1.84
  3. Carmen Mota Reyes · 8 shared papers, 2017–2025 · strength 1.16
  4. Alexander Muckenhuber · 8 shared papers, 2019–2025 · strength 0.92
  5. Christoph W. Michalski · 13 shared papers, 2011–2025 · strength 0.84
  6. Bo Kong · 9 shared papers, 2011–2025 · strength 0.77
  7. Jorg H. Kleeff · 15 shared papers, 2011–2025 · strength 0.73
  8. Hana Algül · 7 shared papers, 2013–2025 · strength 0.71
  9. Lei Ren · 5 shared papers, 2020–2025 · strength 0.65
  10. Roland Michael Schmid · 6 shared papers, 2019–2025 · strength 0.63
  11. Okan Safak · 4 shared papers, 2020–2025 · strength 0.56
  12. Wilko Weichert · 6 shared papers, 2018–2021 · strength 0.53
  13. Achim Krüger · 3 shared papers, 2023–2025 · strength 0.51
  14. Florian Scheufele · 4 shared papers, 2018–2020 · strength 0.50
  15. Stephan Schorn · 7 shared papers, 2013–2020 · strength 0.48
  16. Maximilian Reichert · 4 shared papers, 2020–2025 · strength 0.46
  17. Linhan Ye · 3 shared papers, 2023–2025 · strength 0.45
  18. Kıvanç Görgülü · 3 shared papers, 2023–2025 · strength 0.45
  19. Rickmer Braren · 6 shared papers, 2015–2021 · strength 0.44
  20. Marc Eric Martignoni · 4 shared papers, 2013–2025 · strength 0.42
  21. Chao Fang · 2 shared papers, 2025 · strength 0.41
  22. Yifeng Sun · 2 shared papers, 2025 · strength 0.41
  23. Ingrid Herr · 2 shared papers, 2025 · strength 0.41
  24. Jan Goesta D’Haese · 5 shared papers, 2014–2020 · strength 0.40
  25. Mert Erkan · 9 shared papers, 2011–2015 · strength 0.37

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.